Lantheus Holdings received a Complete Response Letter from the FDA, delaying approval of its LNTH-2501 PET imaging kit for neuroendocrine tumors due to unresolved manufacturing facility issues. The FDA did not raise any concerns about the drug's safety or effectiveness. Lantheus is working with its manufacturing partner and the FDA to resolve these issues and hopes to bring the product to market soon. LNTH-2501 is designed to help locate somatostatin receptor-positive neuroendocrine tumors using PET scans but is not yet FDA approved or available for sale in the U.S.
AI/R Compass UOL, a subsidiary of AI/R specializing in Agentic AI, won the 2026 AWS Partner Network Award as Consulting Partner of the Year for Brazil. This award highlights the company's leadership in data engineering and complex infrastructure usin...
The 2026 CapitalCIO ORBIE Awards honored leading chief information officers from major organizations like Marriott International and NASA for their outstanding leadership and impact in technology. The event highlighted CIOs driving business transform...
The Fédération Internationale de l'Automobile (FIA) reported its best financial performance in 10 years for fiscal 2025, achieving an operating profit of €6.7 million, a 43% increase from the previous year, and reversing a €24 million loss in 2021. R...
Kyivstar, part of VEON Group, signed a Memorandum of Understanding with Ukraine's Ministry of Economy to develop a sovereign AI-ready data center. This initiative aims to enhance Ukraine's digital infrastructure, secure sensitive data within the coun...
AllianceBernstein National Municipal Income Fund announced its financial results for the second fiscal quarter ending April 30, 2026. The fund reported total net investment income of $4.3 million, or $0.15 per share, while experiencing a net realized...
